** Eye-drug maker Harrow's HROW shares rise 2.09% to $31.32

** Brokerage H.C. Wainwright starts coverage on HROW with "buy" rating; sets PT at $57

** Brokerage sees rapid growth driven by co's branded products for eye diseases

** Expects HROW to continue to make meaningful and sensible buys

** Says its eye drop Vevye compares well to other dry eye treatments

** Says that other eye products that are used during surgical procedures such as Iheezo and Triesence also serve as growth drivers

** The PT is a 84.5% upside to the stock's last close

** Stock rose ~232% in the last 12 months

(Reporting by Siddhi Mahatole)

((siddhiprabhanjan.mahatole@thomsonreuters.com))